Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
2001 1
2002 3
2004 2
2005 1
2006 2
2007 1
2008 1
2009 2
2010 1
2011 1
2012 1
2013 2
2014 3
2015 1
2016 1
2017 5
2019 1
2020 3
2021 2
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
The Phenotypic Continuum of ATP1A3-Related Disorders.
Vezyroglou A, Akilapa R, Barwick K, Koene S, Brownstein CA, Holder-Espinasse M, Fry AE, Németh AH, Tofaris GK, Hay E, Hughes I, Mansour S, Mordekar SR, Splitt M, Turnpenny PD, Demetriou D, Koopmann TT, Ruivenkamp CAL, Agrawal PB, Carr L, Clowes V, Ghali N, Holder SE, Radley J, Male A, Sisodiya SM, Kurian MA, Cross JH, Balasubramanian M. Vezyroglou A, et al. Neurology. 2022 Oct 4;99(14):e1511-e1526. doi: 10.1212/WNL.0000000000200927. Epub 2022 Jul 18. Neurology. 2022. PMID: 36192182 Free PMC article. Review.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Ridker PM, et al. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28845751 Free article. Clinical Trial.
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas.
Sweha SR, Chung C, Natarajan SK, Panwalkar P, Pun M, Ghali A, Bayliss J, Pratt D, Shankar A, Ravikumar V, Rao A, Cieslik M, Wilder-Romans K, Scott AJ, Wahl DR, Jessa S, Kleinman CL, Jabado N, Mackay A, Jones C, Martinez D, Santi M, Judkins AR, Yadav VN, Qin T, Phoenix TN, Koschmann CJ, Baker SJ, Chinnaiyan AM, Venneti S. Sweha SR, et al. Sci Transl Med. 2021 Oct 13;13(615):eabf7860. doi: 10.1126/scitranslmed.abf7860. Epub 2021 Oct 13. Sci Transl Med. 2021. PMID: 34644147 Free PMC article.
High-grade gliomas with arginine or valine substitutions of the histone H3.3 glycine-34 residue (H3.3G34R/V) carry a dismal prognosis, and current treatments, including radiotherapy and chemotherapy, are not curative. Because H3.3G34R/V mutations reprogram epigeneti …
High-grade gliomas with arginine or valine substitutions of the histone H3.3 glycine-34 residue (H3.3G34R/V) carry a dismal prognosis …
Genomic Diagnosis of Rare Pediatric Disease in the United Kingdom and Ireland.
Wright CF, Campbell P, Eberhardt RY, Aitken S, Perrett D, Brent S, Danecek P, Gardner EJ, Chundru VK, Lindsay SJ, Andrews K, Hampstead J, Kaplanis J, Samocha KE, Middleton A, Foreman J, Hobson RJ, Parker MJ, Martin HC, FitzPatrick DR, Hurles ME, Firth HV; DDD Study. Wright CF, et al. N Engl J Med. 2023 Apr 27;388(17):1559-1571. doi: 10.1056/NEJMoa2209046. Epub 2023 Apr 12. N Engl J Med. 2023. PMID: 37043637 Free PMC article.
Therapeutic potential of vasopressin receptor antagonists.
Ali F, Guglin M, Vaitkevicius P, Ghali JK. Ali F, et al. Drugs. 2007;67(6):847-58. doi: 10.2165/00003495-200767060-00002. Drugs. 2007. PMID: 17428103 Review.
Three receptor subtypes that mediate the actions of AVP have been identified (V(1A), V(2) and V(1B)). Activation of V(1A) receptors located in vascular smooth muscle cells and the myocardium results in vasoconstriction and increased afterload and hyper …
Three receptor subtypes that mediate the actions of AVP have been identified (V(1A), V(2) and V(1B)). Activation of …
Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections.
El Ghali A, Kunz Coyne AJ, Lucas K, Tieman M, Xhemali X, Lau S-p, Iturralde G, Purdy A, Holger DJ, Garcia E, Veve MP, Rybak MJ. El Ghali A, et al. Microbiol Spectr. 2024 Feb 6;12(2):e0310823. doi: 10.1128/spectrum.03108-23. Epub 2024 Jan 11. Microbiol Spectr. 2024. PMID: 38206034 Free PMC article.
This multi-center, retrospective cohort study evaluated the real-world application of CFDC across six U.S. medical centers from January 2018 to May 2023. Patients aged 18 years and who had received 72 hours of CFDC were included. ...
This multi-center, retrospective cohort study evaluated the real-world application of CFDC across six U.S. medical centers from Janua …
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes.
El Ghali A, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz MG, Vemula R, Wadle C, Philley JV, Mejia-Chew C, Hamad Y, Stevens RW, Zeuli JD, Webb AJ, Fiske CT, Simonyan A, Cimino CL, Mammadova M, Umana VE, Hasbun R, Butt S, Molina KC, Thomas M, Kaip EA, Bouchard J, Gore TW, Howard C, Cabanilla MG, Holger DJ, Frens JJ, Barger M, Ong A, Cohen KA, Rybak MJ. El Ghali A, et al. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0082423. doi: 10.1128/aac.00824-23. Epub 2023 Sep 28. Antimicrob Agents Chemother. 2023. PMID: 37768312 Free PMC article.
Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, including Mycobacteroides abscessus (MAB). This multicenter retrospective study across 16 U.S. medical institutions from January 2020 to Ma …
Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, includ …
A Leadless Intracardiac Transcatheter Pacing System.
Reynolds D, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, Narasimhan C, Steinwender C, Brugada J, Lloyd M, Roberts PR, Sagi V, Hummel J, Bongiorni MG, Knops RE, Ellis CR, Gornick CC, Bernabei MA, Laager V, Stromberg K, Williams ER, Hudnall JH, Ritter P; Micra Transcatheter Pacing Study Group. Reynolds D, et al. N Engl J Med. 2016 Feb 11;374(6):533-41. doi: 10.1056/NEJMoa1511643. Epub 2015 Nov 9. N Engl J Med. 2016. PMID: 26551877 Free article. Clinical Trial.
The primary efficacy end point was the percentage of patients with low and stable pacing capture thresholds at 6 months (2.0 V at a pulse width of 0.24 msec and an increase of 1.5 V from the time of implantation). ...
The primary efficacy end point was the percentage of patients with low and stable pacing capture thresholds at 6 months (2.0 V at a p …
Ectatic Coronary Arteries: Diversity at Its Finest.
Belharty N, Fertat O, El Ghali T, Tabti F, Benmessaoud FA, Oukerraj L, Cherti M. Belharty N, et al. Cureus. 2023 May 1;15(5):e38381. doi: 10.7759/cureus.38381. eCollection 2023 May. Cureus. 2023. PMID: 37265918 Free PMC article.
We illustrate three different angiographic subsets, co-existing with myocardial bridge/coronary slow flow and diversely presenting as asymptomatic, pauci, and frankly symptomatic with stable and acute coronary syndrome. These cases illuminate the diversity of CAE's clinica …
We illustrate three different angiographic subsets, co-existing with myocardial bridge/coronary slow flow and diversely presenting as asympt …
41 results